#### 1 November 2018

## THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY RENALYTIX AI PLC TO CONSTITUTE INSIDE INFORMATION IN RELATION TO THE COMPANY'S QUOTED SECURITIES AS STIPULATED UNDER ARTICLE 7 OF REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

### **Renalytix AI plc**

("RenalytixAI" or the "Company")

### Update regarding AIM admission of RenalytixAI

Renalytix AI plc, which develops artificial intelligence ("AI") enabled clinical decision support solutions for kidney disease, announces that, further to the announcement by EKF Diagnostics Holdings plc ("EKF") on 31 October confirming that RenalytixAl's had successfully raised £22.25 million in gross proceeds, admission to trading on AIM will now take place on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.

Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.

**Enquiries:** 

**Renalytix AI plc** James McCullough, CEO

# N+1 Singer (Nominated Adviser & Broker)

Aubrey Powell / James White / George Tzimas (Corporate Finance) Tom Salvesen / Ross Penney (Corporate Broking)

Walbrook PR Limited Paul McManus / Lianne Cawthorne Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07584 391 303

### About RenalytixAI

RenalytixAI is a developer of artificial intelligence ("AI") enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAl's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.


RenalytixAl's technology platform will draw from distinct sources of patient data, including systems containing extensive electronic health records, predictive blood-based biomarkers and other genomic information for analysis by high-performance, learning computer algorithms (machine learning). RenalytixAl intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.

In May 2018, RenalytixAl secured a cornerstone collaboration with the Icahn School of Medicine at Mount Sinai ("Mount Sinai"), the medical school of the Mount Sinai Health System, for product development and intended commercialisation by RenalytixAI beginning in 2019. As part of the collaboration, Mount Sinai became a shareholder in RenalytixAI and will make a further equity investment in the Fundraising.

In 2019, RenalytixAI expects to launch KidneyIntelX<sup>TM</sup>, an AI-enabled, clinical-laboratory based solution intended to support physician decision making by improving identification, prediction, and risk stratification of patients with

www.renalytixai.com Via Walbrook PR or Tel: +1 646 397 3970

Tel: 020 7496 3000





progressive kidney disease. *KidneyIntelX*<sup>TM</sup> is being designed to combine disparate data sources, including blood-based biomarkers, genetic factors and EHR data, for processing by machine learning algorithms.

RenalytixAI considers there to be a significant opportunity to deliver the first quality-assured, regulated, AI-driven product for the chronic kidney disease ("**CKD**") market.